Interleukin-17A is a potential therapeutic target predicted by proteomics for systemic sclerosis patients at high risk of pulmonary arterial hypertension
Yuuichi Ono, Akira Mogami, Ryuta Saito, Noriyasu Seki, Sho Ishigaki, Hiroshi Takei, Keiko Yoshimoto, Kenji Chiba, Tsutomu Takeuchi, Yuko Kaneko · 2024
Read Interleukin-17A is a potential therapeutic target predicted by proteomics for systemic sclerosis patients at high risk of pulmonary arterial hypertension by Yuuichi Ono, Akira Mogami, Ryuta Saito, Noriyasu Seki, Sho Ishigaki, Hiroshi Takei, Keiko Yoshimoto, Kenji Chiba, Tsutomu Takeuchi, Yuko Kaneko (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11603215.txt.
Description
Yuuichi Ono and nine co-authors search blood proteins for drug targets in systemic sclerosis patients at high risk of lung artery hypertension. That lung complication is a major threat in this autoimmune disease. In the study group of 57 patients, about one fifth had the condition and three quarters met high risk criteria.
Protein profiling compares high risk patients with others and flags raised proteins. Pathway analysis points to interleukin-17A as a top upstream driver. A dual action antibody that blocks both that signal and the interleukin-6 receptor broadly suppressed the raised downstream signals in cell tests. The authors propose interleukin-17A as a target for early intervention in high risk patients.
Catalog record
| CREATOR | Yuuichi Ono, Akira Mogami, Ryuta Saito, Noriyasu Seki, Sho Ishigaki, Hiroshi Takei, Keiko Yoshimoto, Kenji Chiba, Tsutomu Takeuchi, Yuko Kaneko |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |